Compare Torrent Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs ASTRAZENECA PHARMA - Comparison Results

TORRENT PHARMA     Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA ASTRAZENECA PHARMA TORRENT PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 58.4 72.3 80.7% View Chart
P/BV x 6.2 20.4 30.3% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 TORRENT PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-18
TORRENT PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5501,278 121.3%   
Low Rs1,144883 129.6%   
Sales per share (Unadj.) Rs354.7228.4 155.3%  
Earnings per share (Unadj.) Rs40.110.4 386.7%  
Cash flow per share (Unadj.) Rs64.216.3 395.0%  
Dividends per share (Unadj.) Rs14.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs273.198.8 276.5%  
Shares outstanding (eoy) m169.2225.00 676.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.84.7 80.3%   
Avg P/E ratio x33.6104.2 32.2%  
P/CF ratio (eoy) x21.066.4 31.6%  
Price / Book Value ratio x4.910.9 45.1%  
Dividend payout %34.90-   
Avg Mkt Cap Rs m227,89727,008 843.8%   
No. of employees `00014.71.4 1,084.1%   
Total wages/salary Rs m11,3531,535 739.4%   
Avg. sales/employee Rs Th4,083.04,210.9 97.0%   
Avg. wages/employee Rs Th772.31,132.2 68.2%   
Avg. net profit/employee Rs Th461.3191.1 241.4%   
INCOME DATA
Net Sales Rs m60,0215,710 1,051.2%  
Other income Rs m2,988123 2,439.5%   
Total revenues Rs m63,0095,833 1,080.3%   
Gross profit Rs m13,493463 2,914.8%  
Depreciation Rs m4,086147 2,772.0%   
Interest Rs m3,0850-   
Profit before tax Rs m9,310438 2,125.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,529179 1,413.5%   
Profit after tax Rs m6,781259 2,617.3%  
Gross profit margin %22.58.1 277.3%  
Effective tax rate %27.240.8 66.5%   
Net profit margin %11.34.5 249.0%  
BALANCE SHEET DATA
Current assets Rs m52,6233,209 1,639.8%   
Current liabilities Rs m52,0222,070 2,513.7%   
Net working cap to sales %1.020.0 5.0%  
Current ratio x1.01.6 65.2%  
Inventory Days Days12072 165.3%  
Debtors Days Days7635 218.3%  
Net fixed assets Rs m85,016790 10,757.5%   
Share capital Rs m84650 1,692.4%   
"Free" reserves Rs m45,3762,419 1,875.6%   
Net worth Rs m46,2222,469 1,871.9%   
Long term debt Rs m41,1150-   
Total assets Rs m142,4324,605 3,092.7%  
Interest coverage x4.0NM-  
Debt to equity ratio x0.90-  
Sales to assets ratio x0.41.2 34.0%   
Return on assets %6.95.6 123.1%  
Return on equity %14.710.5 139.8%  
Return on capital %14.217.7 80.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m14,580300 4,867.3%   
Fx outflow Rs m3,6002,015 178.7%   
Net fx Rs m10,980-1,715 -640.1%   
CASH FLOW
From Operations Rs m8,94288 10,172.7%  
From Investments Rs m-47,070-94 50,287.9%  
From Financial Activity Rs m34,174NA-  
Net Cashflow Rs m-3,655-6 64,122.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 7.0 0.3 2,340.0%  
FIIs % 12.6 15.7 80.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 9.1 96.7%  
Shareholders   26,511 12,856 206.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   BIOCON   CADILA HEALTHCARE  SUVEN LIFESCIENCES  PLETHICO PHARMA  WOCKHARDT  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 642 Points; Automobile and Realty Stocks Plunge(Closing)

Indian share markets fell sharply today amid fears of rising crude oil prices and weakness in the rupee rattled investor sentiment.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Sep 17, 2019 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA - FRESENIUS KABI ONCO. COMPARISON

COMPARE TORRENT PHARMA WITH

MARKET STATS